Wall Street analysts recommend buying Exicure. Why’s that?

Wall Street analysts recommend buying Exicure. Why’s that?

Modern medicine is truly astonishing. How great are the things scientists can do or aspire to do in the future. Nothing seems impossible. While we admit our current shortcomings, there is an underlying belief that humanity can overcome all these obstacles, given enough time and motivation.

Numerous medical companies are working on different subjects tirelessly. If you feel a little altruistic, then such stocks are for you. If you chose the right company, they could make good investments not only for you but also for humanity.

Exicure is one of such firms. It develops a new class of gene-regulating and immunomodulatory drugs. They feature Exicure’s spherical nucleic acid (SNA) architecture that is specifically designed to unravel therapeutic oligonucleotides’ potential in a range of tissues and cells.

Furthermore, the company has begun its Phase 2 dose expansion evaluating AST-008 in patients with metastatic or advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma in cases when the patients have progressed on single-agent checkpoint therapy.

Exicure plans to use the therapy in combination with pembrolizumab in MCC or cemiplimab for CSCC. The firm has already opened trial sites and begun enrollment during Q2 2020. It will release safety data on AST-008 alone or in combination with pembrolizumab at the AACR meeting on June 22-24.

The company is also exploring other neurological conditions, including Batten disease, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), and Huntington’s disease. According to Wangzhi Li, Ladenburg analyst, Exicure will partner with Friedreich’s Ataxia Research Alliance to advance its program.

How much could investors gain with this stock

Lee stated that, with an $18 price target, Exicure’s shares could skyrocket 562% higher in the next twelve months. Wall Street analysts agree with him. With the $10 average price target, Exicure has a 268% upside potential.

The stock is currently trading at $2.72 per share. Analysts think that such a share price presents investors with a unique buying opportunity.